269 related articles for article (PubMed ID: 12592346)
21. [Anti tumor activity of farnesyl transferase inhibitor].
Yoshimatsu K; Nagasu T
Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
[TBL] [Abstract][Full Text] [Related]
22. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS.
Cohen-Jonathan E; Toulas C; Ader I; Monteil S; Allal C; Bonnet J; Hamilton AD; Sebti SM; Daly-Schveitzer N; Favre G
Radiat Res; 1999 Oct; 152(4):404-11. PubMed ID: 10477917
[TBL] [Abstract][Full Text] [Related]
23. Farnesyltransferase inhibitor FTI-277 prevents autocrine growth stimulation of neuroblastoma by BDNF.
Girgert R; Wittrock J; Pfister S; Schweizer P
J Cancer Res Clin Oncol; 2003 Apr; 129(4):227-33. PubMed ID: 12700894
[TBL] [Abstract][Full Text] [Related]
24. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.
Du W; Prendergast GC
Cancer Res; 1999 Nov; 59(21):5492-6. PubMed ID: 10554025
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
Ageberg M; Rydström K; Lindén O; Linderoth J; Jerkeman M; Drott K
Exp Cell Res; 2011 May; 317(8):1179-91. PubMed ID: 21324313
[TBL] [Abstract][Full Text] [Related]
26. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression.
Zhang B; Prendergast GC; Fenton RG
Cancer Res; 2002 Jan; 62(2):450-8. PubMed ID: 11809695
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model.
Pollack IF; Bredel M; Erff M; Hamilton AD; Sebti SM
Neurosurgery; 1999 Nov; 45(5):1208-14; discussion 1214-5. PubMed ID: 10549939
[TBL] [Abstract][Full Text] [Related]
28. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors.
Wittrock J; Schweizer P; Girgert R
Anticancer Res; 2002; 22(6C):4205-9. PubMed ID: 12553057
[TBL] [Abstract][Full Text] [Related]
29. Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma.
Santucci R; Mackley PA; Sebti S; Alsina M
Cancer Control; 2003; 10(5):384-7. PubMed ID: 14581893
[TBL] [Abstract][Full Text] [Related]
30. The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
Ashar HR; James L; Gray K; Carr D; McGuirk M; Maxwell E; Black S; Armstrong L; Doll RJ; Taveras AG; Bishop WR; Kirschmeier P
Exp Cell Res; 2001 Jan; 262(1):17-27. PubMed ID: 11120601
[TBL] [Abstract][Full Text] [Related]
31. Requirement of c-jun N-terminal kinase for apoptotic cell death induced by farnesyltransferase inhibitor, farnesylamine, in human pancreatic cancer cells.
Mizukami Y; Ura H; Obara T; Habiro A; Izawa T; Osanai M; Yanagawa N; Tanno S; Kohgo Y
Biochem Biophys Res Commun; 2001 Oct; 288(1):198-204. PubMed ID: 11594773
[TBL] [Abstract][Full Text] [Related]
32. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.
van Golen KL; Bao L; DiVito MM; Wu Z; Prendergast GC; Merajver SD
Mol Cancer Ther; 2002 Jun; 1(8):575-83. PubMed ID: 12479217
[TBL] [Abstract][Full Text] [Related]
33. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
Sun J; Ohkanda J; Coppola D; Yin H; Kothare M; Busciglio B; Hamilton AD; Sebti SM
Cancer Res; 2003 Dec; 63(24):8922-9. PubMed ID: 14695209
[TBL] [Abstract][Full Text] [Related]
34. [Farnesyl transferase inhibitors: one target may be found in another].
Mazières J; Pradines A; Favre G
Med Sci (Paris); 2003 Feb; 19(2):211-6. PubMed ID: 12836615
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of tumor response by farnesyltransferase inhibitor in C3H/HeJ hepatocarcinoma.
Kim J; Seong J; Kim SH
Ann N Y Acad Sci; 2004 Dec; 1030():95-102. PubMed ID: 15659785
[TBL] [Abstract][Full Text] [Related]
36. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.
Zeng PY; Rane N; Du W; Chintapalli J; Prendergast GC
Oncogene; 2003 Feb; 22(8):1124-34. PubMed ID: 12606940
[TBL] [Abstract][Full Text] [Related]
37. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
Feldkamp MM; Lau N; Roncari L; Guha A
Cancer Res; 2001 Jun; 61(11):4425-31. PubMed ID: 11389071
[TBL] [Abstract][Full Text] [Related]
38. c-myc down-regulation induces apoptosis in human cancer cell lines exposed to RPR-115135 (C31H29NO4), a non-peptidomimetic farnesyltransferase inhibitor.
Russo P; Arzani D; Trombino S; Falugi C
J Pharmacol Exp Ther; 2003 Jan; 304(1):37-47. PubMed ID: 12490573
[TBL] [Abstract][Full Text] [Related]
39. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.
Moasser MM; Sepp-Lorenzino L; Kohl NE; Oliff A; Balog A; Su DS; Danishefsky SJ; Rosen N
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1369-74. PubMed ID: 9465021
[TBL] [Abstract][Full Text] [Related]
40. Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor.
Kusama T; Mukai M; Tatsuta M; Matsumoto Y; Nakamura H; Inoue M
Clin Exp Metastasis; 2003; 20(6):561-7. PubMed ID: 14598891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
